The Latest on Acute Lymphocytic Leukemia
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
Updates in Myelodysplastic Syndromes
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
FDA Approves First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate CancerMay 30th 2023
The FDA has approved flotufolastat F 18 injection (Posluma) for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen level.
Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AMLMay 29th 2023
Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients.
Shifts In Ovarian Cancer Treatment Options Necessitate Continued ResearchMay 29th 2023
Whitfield B. Growdon, MD, discusses the role PARP inhibitors have played in ovarian cancer since their introduction to the field, the updated clinical trial data that contributed to the indication withdrawals for these agents, and where future research in this area may be headed.
GCC’s Pharmacogenomics Program May Help Reduce Side Effects from Chemotherapy for Some PatientsMay 29th 2023
The Georgia Cancer Center Pharmacogenomics Program has launched its pharmacogenomics testing services for Georgia Cancer Center patients and oncologists.
Latinx Patients Highlight Barriers to Tumor Genomic Profiling for CancerMay 29th 2023
Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.
Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer SubtypesMay 28th 2023
Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.
Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLLMay 27th 2023
The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.
Improving Durability of Responses Is a Key Next Step for CAR T-cell Therapy in Myeloma
Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.
Liver Cancer Awareness Higher in Individuals Who Receive HBV/HCV ScreeningMay 26th 2023
Individuals in Philadelphia and New York City who were screened for the common liver cancer risk factors hepatitis B virus or hepatitis C virus displayed a higher level of knowledge of liver cancer.
BET Inhibition Highlights Exploration of Novel Targeted Approaches in Myelofibrosis
Andrew T. Kuykendall, MD, expands on the rationale for exploring BET inhibition in the treatment of patients with myelofibrosis, details the implications of data from the MANIFEST trial, and discusses other potential targets for novel therapies for myelofibrosis.
European Approval Sought for Cilta-cel in Relapsed and Lenalidomide-Refractory MyelomaMay 26th 2023
A Type II variation application seeking the approval of ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma has been submitted to the European Medicines Agency.
EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLCMay 26th 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based chemotherapy for patients with resectable non–small cell lung cancer at high risk of recurrence and tumor cell PD-L1 expression of at least 1%.
Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial CancerMay 26th 2023
The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed, advanced or recurrent endometrial cancer.
Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to Remove Lymph NodesMay 26th 2023
Austin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons.
Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AMLMay 26th 2023
Japan’s Ministry of Health, Labour, and Welfare has approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation and as maintenance monotherapy in patients with newly diagnosed acute myeloid leukemia whose tumors harbor FLT3-ITD mutations.
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing DisparitiesMay 25th 2023
Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.
Luspatercept Nearly Doubles Likelihood of Transfusion Independence in Lower-Risk MDSMay 25th 2023
Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.
Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical CancerMay 25th 2023
Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the KEYNOTE-826 trial.
Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic CancerMay 25th 2023
Minimally invasive distal pancreatectomy was found to be a safe and effective alternative to that of open distal pancreatectomy in patients with resectable pancreatic cancer, confirmed by a noninferior radical resection rate, lymph node yield, and comparable survival data.